	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	C 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	C 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR
Total Revenue	123.92	137.70	189.42	185.33	162.11	169.73	191.65	230.93	279.89	307.56	278.36	301.36	332.62	364.91	445.10	489.81
Cost of Operating Revenue	8.49	2.61	5.09	-21.78	-16.16	15.40	17.15	100.32	119.78	128.84	118.27	108.53	107.00	116.76	187.57	230.47
Gross Profit	115.43	135.10	184.33	207.10	178.26	154.33	174.50	130.61	160.11	178.72	160.09	192.84	225.62	248.15	257.53	259.33
Gross Margin	93.2	98.1	97.3	111.8	110.0	90.9	91.1	56.6	57.2	58.1	57.5	64.0	67.8	68.0	57.9	52.9
Total Operating Expenses	113.94	122.31	160.74	154.97	141.50	143.95	152.16	189.13	226.66	243.54	244.21	255.63	286.01	317.89	396.63	444.49
Operating Profit	9.97	15.39	28.68	30.36	20.60	25.77	39.49	41.80	53.23	64.02	34.15	45.73	46.62	47.02	48.47	45.31
Operating Margin	8.0	11.2	15.1	16.4	12.7	15.2	20.6	18.1	19.0	20.8	12.3	15.2	14.0	12.9	10.9	9.3
Financing Income/(Expense) - Net	-1.81	-3.67	-3.76	-4.59	-6.23	-9.66	-10.31	-3.24	-5.02	-7.73	-9.46	-9.67	-8.80	-6.25	-8.70	-17.06
Profit before Taxes	9.08	12.30	25.51	26.35	15.08	16.75	30.05	38.87	48.51	56.75	-63.39	36.16	41.56	40.58	46.30	41.35
Income Taxes	-0.13	0.54	1.20	0.93	0.91	0.47	0.64	0.43	-1.98	1.09	3.95	1.15	1.95	1.98	4.67	4.73
Profit after Tax	9.20	11.75	24.30	25.40	14.17	16.28	29.42	38.43	50.48	55.66	-67.34	35.01	39.62	38.60	41.63	36.61
PAT Margin	7.4	8.5	12.8	13.7	8.7	9.6	15.4	16.6	18.0	18.1	-24.2	11.6	11.9	10.6	9.4	7.5
EPS - Basic - ex Extraordinary Items	5.75	7.34	15.19	15.87	8.85	10.17	17.83	20.22	26.57	29.29	-35.43	18.42	20.85	20.31	21.91	19.22
EPS - Diluted - ex Extraordinary Items	5.75	7.34	15.19	15.87	8.85	10.17	17.83	20.22	26.57	29.29	-35.43	18.42	20.85	20.31	21.91	19.22
EBIT	9.97	15.39	28.68	30.36	20.60	25.77	39.49	41.80	53.23	64.02	34.15	45.73	46.62	47.02	48.47	45.31
EBITDA	14.67	19.90	33.34	34.75	24.51	28.81	40.45	43.25	54.68	66.84	37.24	48.75	49.88	50.83	52.44	49.31
EBITDA Margin	11.8	14.5	17.6	18.7	15.1	17.0	21.1	18.7	19.5	21.7	13.4	16.2	15.0	13.9	11.8	10.1

Balance Sheet

Abridged

Understanding Balance Sheet

Nath Bio-Genes (India) Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	96	120	159	198	225	242	354	407	477	524	470	521	572	690	779
Long-Term Investments	1	0	0	0	0	5	5	5	5	5	5	5	6	6	6
Property Plant & Equipment - Net	6	26	8	8	194	207	207	228	231	233	233	234	241	243	244
Total Non-Current Assets	24	39	31	28	207	213	217	239	253	266	272	272	309	336	319
Total Assets	120	158	190	226	432	455	571	646	730	790	742	793	880	1,026	1,097
Total Current Liabilities	72	98	105	116	129	130	100	136	170	173	197	216	262	365	395
Long Term Debt	1	1	1	1	15	20	0	1	0	1	1	0	5	13	17
Total Non-Current Liabilities	2	3	3	3	17	22	2	2	3	3	3	3	8	17	22
Total Liabilities	74	101	108	119	145	152	102	138	172	176	200	220	270	382	417
Total Shareholders' Equity	46	57	82	107	287	303	469	508	558	613	542	573	610	644	680
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-
Total Equity	46	57	82	107	287	303	469	508	558	613	542	573	610	644	680
Total Liabilities & Equity	120	158	190	226	432	455	571	646	730	790	742	793	880	1,026	1,097

Cash Flow

Abridged

Understanding Cash Flow Statement

Nath Bio-Genes (India) Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2013 Mar 31	2014 Mar 31	2015 Mar 31	C 2016 Mar 31	C 2017 Mar 31	2018 Mar 31	C 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2013 Mar 31	2014 Mar 31	2015 Mar 31	C 2016 Mar 31	C 2017 Mar 31	2018 Mar 31	C 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	16.49	28.89	31.23	19.12	19.91	30.36	37.23	48.74	58.64	25.60	38.08	42.71	45.64	47.14
Working Capital - Increase/(Decrease)	-5.95	-17.82	-29.06	-38.91	-26.22	-87.16	-63.64	-44.51	-65.13	-18.07	-9.81	23.09	-34.95	-69.17
Net CF from Operating Activities	10.54	11.06	2.17	-19.80	-6.31	-56.79	-26.41	4.23	-6.49	7.53	28.26	65.80	10.69	-22.04
Capital Expenditures - Net	21.27	2.80	0.68	7.01	4.05	4.57	22.21	15.74	3.71	1.04	2.50	26.73	7.82	2.95
Net CF from Investing Activities	-20.77	-15.79	-2.04	-17.11	-4.05	-4.57	-22.21	-15.74	-11.50	-20.96	-2.90	-27.72	-7.55	-3.07
Dividends Paid - Cash - Total	-	-	-	-	-	-	-	-	-	3.80	3.80	3.80	3.80	3.80
Stock - Issuance/(Retirement) - Net	-	-	-	-	-	136.50	-	-	-	-	-	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	9.40	4.49	-0.73	37.46	14.99	-36.33	25.34	12.11	25.22	-7.82	12.25	5.13	12.15	16.00
Net Cash Flow from Financing Activities	9.42	4.46	-0.78	36.55	14.99	100.17	25.34	12.11	25.22	-11.62	8.45	1.33	8.35	12.20
Free Cash Flow to Equity	-1.33	12.76	0.76	10.65	4.63	-97.69	-23.28	0.60	15.02	-1.33	38.02	44.21	15.03	-8.98
Free Operating CF net dividend	-10.82	8.17	1.47	-26.86	-10.44	-61.65	-48.71	-11.97	-10.35	2.61	21.91	35.23	-1.03	-28.84
Free Operating CF	-10.82	8.17	1.47	-26.86	-10.44	-61.65	-48.71	-11.97	-10.35	6.41	25.71	39.03	2.77	-25.04

Business Segment Analysis

FY End:

Mar 26

Nath Bio-Genes (India) Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Seed Cultivation (100.0%)₹ 3.01 Cr

Revenue / Sales

Seed Cultivation (100.0%)₹ 445.10 Cr

Assets

Seed Cultivation (100.0%)₹ 1,097.42 Cr

Operating Income

Seed Cultivation (100.0%)₹ 48.47 Cr

Regional Segment Analysis

FY End:

Mar 26

Nath Bio-Genes (India) Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (98.8%)₹ 439.86 CrOutside India (1.2%)₹ 5.25 Cr

Assets

India (98.1%)₹ 1,076.94 CrOutside India (1.9%)₹ 20.49 Cr

Historical Segment Analysis

Track how Nath Bio-Genes (India) Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2023 Mar 31	2024 Mar 31	2026 Mar 31
	2023 Mar 31	2024 Mar 31	2026 Mar 31
Seed Cultivation	3	27	3

Frequently Asked Questions

What is the revenue of Nath Bio-Genes (India) Ltd.?

The latest trailing twelve month revenue of Nath Bio-Genes (India) Ltd. is ₹ 489.81 Cr, reflecting a 1-year growth of 21.02% and a 3-year CAGR of 14.38%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Nath Bio-Genes (India) Ltd.?

The latest trailing twelve month net profit (PAT) of Nath Bio-Genes (India) Ltd. is ₹ 36.61 Cr, with a 3-year earnings CAGR of -2.21%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Nath Bio-Genes (India) Ltd.?

The trailing twelve month EBITDA of Nath Bio-Genes (India) Ltd. is approximately ₹ 45.31 Cr (based on an operating margin of 9.25%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Nath Bio-Genes (India) Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Nath Bio-Genes (India) Ltd. is 18.43. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Nath Bio-Genes (India) Ltd.?

The debt-to-equity ratio of Nath Bio-Genes (India) Ltd. stands at 0.20. The interest coverage ratio is 2.66x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Nath Bio-Genes (India) Ltd.?

The estimated book value per share of Nath Bio-Genes (India) Ltd. is 358.06 (derived from a P/B ratio of 0.37 and market price of ₹ 131.40), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Nath Bio-Genes (India) Ltd.?

The trailing twelve month operating cash flow of Nath Bio-Genes (India) Ltd. is ₹ -22.04 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Nath Bio-Genes (India) Ltd. report consolidated or standalone financials?

Nath Bio-Genes (India) Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.